An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.
BACKGROUND
Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults.


OBJECTIVE
To update the evidence and provide an overview of the available data on icatibant.


METHODS
Peer reviewed articles published and listed in Medline Search and published updated guidelines for the treatment of acute attacks in hereditary angioedema type I and II in adults were reviewed. The validity and quality of evidence were evaluated.


CONCLUSIONS
Clinical evidence for the treatment of acute hereditary angioedema attacks with icatibant is strong. Approximately 10% of the patients require a second dose. No serious adverse reactions have been reported. The only significant side effects consistently registered by 90% of patients are transient local pain, swelling, and erythema at the local injection site.


CONCLUSIONS
Subcutaneously administered 30 mg icatibant has been shown to be a safe and efficacious treatment in clinical trials. It is the only specific treatment authorized for self-administration by the subcutaneous route offering increased patient independence.
Département d'Anesthésie Réanimation, Centre de Référence des Angioedèmes à Bradykinine, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon.
Bernard
B
Floccard
Etienne
E
Hautin
Laurence
L
Bouillet
Brigitte
B
Coppere
Bernard
B
Allaouchiche